TABLE 3.

Multivariate Analyses of Survival Outcomes

Outcome	Covariate	Comparison	HR	(95% CI)	P
Prostate cancer-specific mortality	Age	<70 vs ≥70	1.21	(0.86, 1.70)	.27
	Race	Black vs Other	0.9	(0.52, 1.56)	.72
	Treatment arm	Arm II vs Arm I	0.57	(0.41, 0.78)	.0004
	Prostatectomy	No vs Yes	0.51	(0.30, 0.87)	.013
	Nodal involvement	No vs Yes	2.22	(1.46, 3.37)	.0002
	Gleason score (Central review)	2–6 vs 7–10	3.47	(2.19, 5.49)	<.0001
	Clinical stage	A-B vs C	1.28	(0.82, 2.02)	.28
	BMI	<25	—
		≥25, <30	1.52	(1.02, 2.28)	.041
		≥30	1.64	(1.01, 2.66)	.043
Nonprostate cancer-specific mortality	Age	<70 vs ≥70	2.12	(1.62, 2.77)	<.0001
	Race	Black vs Other	0.72	(0.49, 1.07)	.11
	Treatment arm	Arm II vs Arm I	0.83	(0.66, 1.05)	.12
	Prostatectomy	No vs Yes	0.58	(0.36, 0.93)	.025
	Nodal involvement	No vs Yes	1.28	(0.89, 1.84)	.19
	Gleason score (Central review)	2–6 vs 7–10	1.43	(1.10, 1.85)	.008
	Clinical stage	A-B vs C	1.60	(1.05, 2.43)	.029
	BMI	<25	—
		≥25, <30	0.95	(0.73, 1.23)	.70
		≥30	0.77	(0.53, 1.11)	.16
All-cause mortality	Age	<70 vs ≥70	1.72	(1.40, 2.12)	<.0001
	Race	Black vs Other	0.78	(0.57, 1.08)	.13
	Treatment arm	Arm II vs Arm I	0.73	(0.60, 0.88)	.0008
	Prostatectomy	No vs Yes	0.54	(0.38, 0.78)	.0009
	Nodal involvement	No vs Yes	1.60	(1.22, 2.10)	.0007
	Gleason score (Central review)	2–6 vs 7–10	1.84	(1.48, 2.30)	<.0001
	Clinical stage	A-B vs C	1.46	(1.07, 1.98)	.016
	BMI	<25	—
		≥25, <30	1.09	(0.88, 1.36)	.42
		≥30	1.00	(0.75, 1.33)	1.00

BMI indicates body mass index; HR, hazard ratio; CI, confidence interval.